GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » EPS (Diluted)

CLGN (CollPlant Biotechnologies) EPS (Diluted) : $-1.54 (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies EPS (Diluted)?

CollPlant Biotechnologies's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.38. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.54.

CollPlant Biotechnologies's EPS (Basic) for the three months ended in Sep. 2024 was $-0.38. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.54.

CollPlant Biotechnologies's EPS without NRI for the three months ended in Sep. 2024 was $-0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.49.

During the past 12 months, CollPlant Biotechnologies's average EPS without NRIGrowth Rate was -2228.60% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, CollPlant Biotechnologies's highest 3-Year average EPS without NRI Growth Rate was 42.20% per year. The lowest was -273.80% per year. And the median was -8.70% per year.


CollPlant Biotechnologies EPS (Diluted) Historical Data

The historical data trend for CollPlant Biotechnologies's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies EPS (Diluted) Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.23 -0.84 0.02 -1.53 -0.62

CollPlant Biotechnologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.38 -0.42 -0.37 -0.37 -0.38

Competitive Comparison of CollPlant Biotechnologies's EPS (Diluted)

For the Biotechnology subindustry, CollPlant Biotechnologies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's PE Ratio distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's PE Ratio falls into.



CollPlant Biotechnologies EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

CollPlant Biotechnologies's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-7.019-0)/11.389
=-0.62

CollPlant Biotechnologies's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.326-0)/11.455
=-0.38

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CollPlant Biotechnologies  (NAS:CLGN) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


CollPlant Biotechnologies EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies Business Description

Traded in Other Exchanges
N/A
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.